ITA6499
ITA6499
- Catalog: ITA6499
- Gene/Protein: APOBEC3G
- Product Description: Immunotag™ APOBEC3G Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | APOBEC3G |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human APOBEC3G |
| Specificity | APOBEC3G Antibody detects endogenous levels of total APOBEC3G |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | APOBEC3G |
| Accession No. | Q9HC16 |
| Alternate Names | A3G; ABC3G_HUMAN; APOBEC related cytidine deaminase; APOBEC related protein; APOBEC-related cytidine deaminase; APOBEC-related protein 9; APOBEC-related protein; APOBEC3G; Apolipoprotein B editing enzyme catalytic polypeptide like 3G; Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G; Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3G; Apolipoprotein B mRNA editing enzyme catalytic subunit 3G; apolipoprotein B mRNA editing enzyme cytidine deaminase; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like; ARCD; ARP-9; ARP9; bK150C2.7; CEM-15; CEM15; deoxycytidine deaminase; dJ494G10.1; DNA dC dU editing enzyme APOBEC 3G; DNA dC->dU editing enzyme; DNA dC->dU-editing enzyme APOBEC-3G; EC 3.5.4.; FLJ12740; MDS019; OTTHUMP00000028911; phorbolin-like protein; phorbolin-like protein MDS019; |
| Description | DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits potent antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV). May inhibit the mobility of LTR and non-LTR retrotransposons. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 46kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|